{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:02:07Z","timestamp":1788930127673,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel coronavirus disease (COVID-19). The neutralizing monoclonal antibodies (mAbs) targeting the receptor-binding domain (RBD) of SARS-CoV-2 are among the most promising strategies to prevent and treat COVID-19. However, SARS-CoV-2 variants of concern (VOCs) profoundly reduced the efficacies of most of mAbs and vaccines approved for clinical use. Herein, we demonstrated mAb 35B5 efficiently neutralizes both wild-type (WT) SARS-CoV-2 and VOCs, including B.1.617.2 (delta) variant, in vitro and in vivo. Cryo-electron microscopy (cryo-EM) revealed that 35B5 neutralizes SARS-CoV-2 by targeting a unique epitope that avoids the prevailing mutation sites on RBD identified in circulating VOCs, providing the molecular basis for its pan-neutralizing efficacy. The 35B5-binding epitope could also be exploited for the rational design of a universal SARS-CoV-2 vaccine.<\/jats:p>","DOI":"10.1038\/s41392-022-00954-8","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T02:03:07Z","timestamp":1649124187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD"],"prefix":"10.1038","volume":"7","author":[{"given":"Xiaofei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiqiong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoyang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0270-9729","authenticated-orcid":false,"given":"Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3620-610X","authenticated-orcid":false,"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-8130","authenticated-orcid":false,"given":"Kai","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-3311","authenticated-orcid":false,"given":"Lilin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"954_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","volume":"384","author":"P Chen","year":"2021","unstructured":"Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. New. Engl. J. Med. 384, 229\u2013237 (2021).","journal-title":"New. Engl. J. Med."},{"key":"954_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. New. Engl. J. Med. 384, 238\u2013251 (2021).","journal-title":"New. Engl. J. Med."},{"key":"954_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jama.2021.0202","volume":"325","author":"RL Gottlieb","year":"2021","unstructured":"Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. J. Am. Med. Assoc. 325, 632\u2013644 (2021).","journal-title":"J. Am. Med. Assoc."},{"key":"954_CR4","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.clinthera.2021.08.009","volume":"43","author":"JY Kim","year":"2021","unstructured":"Kim, J. Y. et al. Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase i studies in healthy individuals and patients with mild SARS-CoV-2 infection. Clin. Ther. 43, 1706\u20131727 (2021).","journal-title":"Clin. Ther."},{"key":"954_CR5","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. New. Engl. J. Med 385, 1941\u20131950 (2021).","journal-title":"New. Engl. J. Med"},{"key":"954_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516\u2013527 (2020).","journal-title":"Nature"},{"key":"954_CR7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.immuni.2021.07.017","volume":"54","author":"K Bok","year":"2021","unstructured":"Bok, K., Sitar, S., Graham, B. S. & Mascola, J. R. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity 54, 1636\u20131651 (2021).","journal-title":"Immunity"},{"key":"954_CR8","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1016\/j.cell.2021.07.027","volume":"184","author":"D Corti","year":"2021","unstructured":"Corti, D., Purcell, L. A., Snell, G. & Veesler, D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 184, 4593\u20134595 (2021).","journal-title":"Cell"},{"key":"954_CR9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.abh1139","volume":"373","author":"M Yuan","year":"2021","unstructured":"Yuan, M. et al. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science 373, 818\u2013823 (2021).","journal-title":"Science"},{"key":"954_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cell.2020.11.020","volume":"184","author":"E Volz","year":"2021","unstructured":"Volz, E. et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell 184, 64\u201375 (2021).","journal-title":"Cell"},{"key":"954_CR11","unstructured":"Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, eabg3055 (2021)."},{"key":"954_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","volume":"592","author":"H Tegally","year":"2021","unstructured":"Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438\u2013443 (2021).","journal-title":"Nature"},{"key":"954_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1126\/science.abh2644","volume":"372","author":"NR Faria","year":"2021","unstructured":"Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815\u2013821 (2021).","journal-title":"Science"},{"key":"954_CR14","doi-asserted-by":"crossref","unstructured":"Cherian, S. et al. SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms 9, 1542 (2021).","DOI":"10.3390\/microorganisms9071542"},{"key":"954_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717\u2013726 (2021).","journal-title":"Nat. Med."},{"key":"954_CR16","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","volume":"184","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384\u20132393 (2021).","journal-title":"Cell"},{"key":"954_CR17","doi-asserted-by":"crossref","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep 36, 109415 (2021).","DOI":"10.1016\/j.celrep.2021.109415"},{"key":"954_CR18","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372\u20132383 (2021).","journal-title":"Cell"},{"key":"954_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.chom.2021.03.009","volume":"29","author":"VV Edara","year":"2021","unstructured":"Edara, V. V. et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell. Host. Microbe 29, 516\u2013521 (2021).","journal-title":"Cell. Host. Microbe"},{"key":"954_CR20","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJMc2102179","volume":"384","author":"K Wu","year":"2021","unstructured":"Wu, K. et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. New. Engl. J. Med. 384, 1468\u20131470 (2021).","journal-title":"New. Engl. J. Med."},{"key":"954_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622 (2021).","journal-title":"Nature"},{"key":"954_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41392-020-00301-9","volume":"5","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal. Transduct. Tar. 5, 180 (2020).","journal-title":"Signal. Transduct. Tar."},{"key":"954_CR23","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cell.2021.01.050","volume":"184","author":"A Sokal","year":"2021","unstructured":"Sokal, A. et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell 184, 1201\u20131213 (2021).","journal-title":"Cell"},{"key":"954_CR24","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"L Bao","year":"2020","unstructured":"Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830\u2013833 (2020).","journal-title":"Nature"},{"key":"954_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","volume":"28","author":"SH Sun","year":"2020","unstructured":"Sun, S. H. et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell. Host. Microbe 28, 124\u2013133 (2020).","journal-title":"Cell. Host. Microbe"},{"key":"954_CR26","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"954_CR27","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"954_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cell.2020.09.035","volume":"183","author":"S Du","year":"2020","unstructured":"Du, S. et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell 183, 1013\u20131023 (2020).","journal-title":"Cell"},{"key":"954_CR29","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"954_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41586-020-2772-0","volume":"588","author":"DJ Benton","year":"2020","unstructured":"Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327\u2013330 (2020).","journal-title":"Nature"},{"key":"954_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"954_CR32","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"954_CR33","doi-asserted-by":"crossref","unstructured":"Romero, P. E. et al. The emergence of SARS-CoV-2 variant lambda (C.37) in South America. Microbiol Spectr 9, e0078921 (2021).","DOI":"10.1128\/Spectrum.00789-21"},{"key":"954_CR34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1126\/science.abd3255","volume":"370","author":"C Toelzer","year":"2020","unstructured":"Toelzer, C. et al. Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. Science 370, 725\u2013730 (2020).","journal-title":"Science"},{"key":"954_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.abf2303","volume":"372","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science 372, 525\u2013530 (2021).","journal-title":"Science"},{"key":"954_CR36","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cell.2020.09.032","volume":"183","author":"L Yurkovetskiy","year":"2020","unstructured":"Yurkovetskiy, L. et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 183, 739\u2013751 (2020).","journal-title":"Cell"},{"key":"954_CR37","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","volume":"184","author":"W Dejnirattisai","year":"2021","unstructured":"Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2939\u20132954 (2021).","journal-title":"Cell"},{"key":"954_CR38","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.chom.2021.04.007","volume":"29","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell. Host. Microbe 29, 747\u2013751 (2021).","journal-title":"Cell. Host. Microbe"},{"key":"954_CR39","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1126\/science.abc5881","volume":"369","author":"Z Lv","year":"2020","unstructured":"Lv, Z. et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science 369, 1505\u20131509 (2020).","journal-title":"Science"},{"key":"954_CR40","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1126\/science.abe3354","volume":"370","author":"MA Tortorici","year":"2020","unstructured":"Tortorici, M. A. et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 370, 950\u2013957 (2020).","journal-title":"Science"},{"key":"954_CR41","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.chom.2020.07.002","volume":"28","author":"J Huo","year":"2020","unstructured":"Huo, J. et al. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. Cell. Host. Microbe 28, 497 (2020).","journal-title":"Cell. Host. Microbe"},{"key":"954_CR42","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1016\/j.cell.2021.04.033","volume":"184","author":"D Asarnow","year":"2021","unstructured":"Asarnow, D. et al. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. Cell 184, 3192\u20133204 (2021).","journal-title":"Cell"},{"key":"954_CR43","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.abb7269","volume":"368","author":"M Yuan","year":"2020","unstructured":"Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630\u2013633 (2020).","journal-title":"Science"},{"key":"954_CR44","doi-asserted-by":"crossref","unstructured":"Cohen, J. South Africa suspends use of AstraZeneca\u2019s COVID-19 vaccine after it fails to clearly stop virus variant. Science Magazine, February 7, 2021. https:\/\/www.sciencemag.org\/news\/2021\/02\/south-africa-suspendsuse-astrazenecas-covid-19-vaccine-after-it-fails-clearly-stop (2021).","DOI":"10.1126\/science.abg9559"},{"key":"954_CR45","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1056\/NEJMc2103022","volume":"384","author":"GL Wang","year":"2021","unstructured":"Wang, G. L. et al. Susceptibility of circulating SARS-CoV-2 variants to neutralization. New. Engl. J. Med. 384, 2354\u20132356 (2021).","journal-title":"New. Engl. J. Med."},{"key":"954_CR46","unstructured":"Herper, M. & Branswell, H. New data shed light on efficacy of J&J\u2019s single-dose covid vaccine. Stat https:\/\/www.statnews\/.com\/2021\/02\/24\/new-data-shed-light-on-efficacy-of-jjs-single-dose-vaccineagainst-covid-19\/ (2021)."},{"key":"954_CR47","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41591-018-0042-6","volume":"24","author":"K Xu","year":"2018","unstructured":"Xu, K. et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat. Med. 24, 857\u2013867 (2018).","journal-title":"Nat. Med."},{"key":"954_CR48","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1126\/science.aae0474","volume":"352","author":"R Kong","year":"2016","unstructured":"Kong, R. et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352, 828\u2013833 (2016).","journal-title":"Science"},{"key":"954_CR49","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.abf4830","volume":"371","author":"CG Rappazzo","year":"2021","unstructured":"Rappazzo, C. G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science 371, 823\u2013829 (2021).","journal-title":"Science"},{"key":"954_CR50","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","volume":"17","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell. Mol. Immunol. 17, 647\u2013649 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"954_CR51","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nprot.2009.3","volume":"4","author":"K Smith","year":"2009","unstructured":"Smith, K. et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4, 372\u2013384 (2009).","journal-title":"Nat. Protoc."},{"key":"954_CR52","doi-asserted-by":"publisher","first-page":"7477","DOI":"10.1007\/s00216-015-8915-8","volume":"407","author":"F Real-Fern\u00e1ndez","year":"2015","unstructured":"Real-Fern\u00e1ndez, F. et al. Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization. Anal. Bioanal. Chem. 407, 7477\u20137485 (2015).","journal-title":"Anal. Bioanal. Chem."},{"key":"954_CR53","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119 (2020).","journal-title":"Nature"},{"key":"954_CR54","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","volume":"182","author":"J Sun","year":"2020","unstructured":"Sun, J. et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182, 734\u2013743 (2020).","journal-title":"Cell"},{"key":"954_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jsb.2005.01.002","volume":"150","author":"J Lei","year":"2005","unstructured":"Lei, J. & Frank, J. Automated acquisition of cryo-electron micrographs for single particle reconstruction on an FEI Tecnai electron microscope. J. Struct. Biol. 150, 69\u201380 (2005).","journal-title":"J. Struct. Biol."},{"key":"954_CR56","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"954_CR57","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"954_CR58","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.str.2011.12.014","volume":"20","author":"R Henderson","year":"2012","unstructured":"Henderson, R. et al. Outcome of the first electron microscopy validation task force meeting. Structure 20, 205\u2013214 (2012).","journal-title":"Structure"},{"key":"954_CR59","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nmeth.2115","volume":"9","author":"SH Scheres","year":"2012","unstructured":"Scheres, S. H. & Chen, S. Prevention of overfitting in cryo-EM structure determination. Nat. Methods 9, 853\u2013854 (2012).","journal-title":"Nat. Methods"},{"key":"954_CR60","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"954_CR61","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D"},{"key":"954_CR62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00954-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T14:09:15Z","timestamp":1669212555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00954-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["954"],"URL":"https:\/\/doi.org\/10.1038\/s41392-022-00954-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.29.470356","asserted-by":"object"}]},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The pending patents of 35B5 and 32C7 have been licensed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}